|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:aims_to
|
reduce bleeding risk
reduce stroke risk
|
|
gptkbp:business_model
|
yes
|
|
gptkbp:completed
|
gptkb:2011
|
|
gptkbp:conducted
|
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
multiple countries
|
|
gptkbp:contributes_to
|
evidence-based medicine
|
|
gptkbp:focuses_on
|
gptkb:atrial_fibrillation
|
|
gptkbp:governed_by
|
institutional review boards
|
|
gptkbp:has_outcome_measures
|
stroke
major bleeding
death from any cause
|
|
gptkbp:has_research_focus
|
apixaban reduces major bleeding by 31%
apixaban reduces stroke risk by 21%
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
The ARISTOTLE Trial
|
|
gptkbp:influences
|
gptkb:guidelines
|
|
gptkbp:involves
|
multiple sites
over 18,000 patients
|
|
gptkbp:is_associated_with
|
gptkb:apixaban
gptkb:warfarin
|
|
gptkbp:is_cited_in
|
numerous studies
|
|
gptkbp:is_compared_to
|
gptkb:apixaban
gptkb:warfarin
|
|
gptkbp:is_funded_by
|
pharmaceutical companies
|
|
gptkbp:is_part_of
|
anticoagulation research
|
|
gptkbp:is_referenced_in
|
gptkb:literature
|
|
gptkbp:is_relevant_to
|
cardiology
thrombosis
stroke prevention
|
|
gptkbp:measures
|
safety
efficacy
|
|
gptkbp:published_in
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:result
|
gptkb:2011
|
|
gptkbp:started_in
|
gptkb:2006
|
|
gptkbp:uses
|
randomized controlled trial design
|
|
gptkbp:was_a_demonstration_of
|
apixaban has a lower risk of major bleeding
apixaban is more effective than warfarin
|
|
gptkbp:bfsParent
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:bfsLayer
|
6
|